Shares in Mesoblast tumbled 17.4 per cent on Tuesday after Swiss pharma giant Novartis Pharmaceuticals terminated its proposed deal to fund development of Mesoblast’s remestemcel-L drug for the potential treatment of ventilator dependent COVID-19 patients.
Silviu Itescu is chief executive and founder of Mesoblast. Luis Ascui
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
